Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

PASG

Passage Bio Inc

Jan 24 • 04:00PM ET

0.6060

Dollar change -0.0114
Percentage change -1.85	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP ADPT NTLA QURE EDIT CLLS BLUE REPL MGTX

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.17	Insider Own	15.93%	Shs Outstand	61.77M	Perf Week	1.00%
Market Cap	37.43M	Forward P/E	-	EPS next Y	-0.66	Insider Trans	-1.69%	Shs Float	51.93M	Perf Month	-8.18%
Income	-68.80M	PEG	-	EPS next Q	-0.21	Inst Own	44.00%	Short Float	7.42%	Perf Quarter	2.54%
Sales	0.00M	P/S	-	EPS this Y	47.04%	Inst Trans	-21.52%	Short Ratio	5.07	Perf Half Y	-26.85%
Book/sh	1.18	P/B	0.51	EPS next Y	33.20%	ROA	-48.97%	Short Interest	3.85M	Perf Year	-31.21%
Cash/sh	1.37	P/C	0.44	EPS next 5Y	26.39%	ROE	-69.15%	52W Range	0.45 - 1.79	Perf YTD	6.86%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-46.23%	ROI	-72.57%	52W High	-66.15%	Beta	1.55
Dividend TTM	-	Quick Ratio	5.15	Sales past 5Y	0.00%	Gross Margin	-	52W Low	34.37%	ATR (14)	0.08
Dividend Ex-Date	-	Current Ratio	5.15	EPS Y/Y TTM	42.87%	Oper. Margin	-	RSI (14)	44.87	Volatility	6.66% 12.77%
Employees	58	Debt/Eq	0.36	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	7.00
Option/Short	Yes / Yes	LT Debt/Eq	0.30	EPS Q/Q	36.72%	Payout	-	Rel Volume	0.13	Prev Close	0.62
Sales Surprise	-100.00%	EPS Surprise	-33.74%	Sales Q/Q	-	Earnings	Nov 13 BMO	Avg Volume	760.42K	Price	0.61
SMA20	-7.56%	SMA50	-10.32%	SMA200	-29.31%	Trades		Volume	101,445	Change	-1.85%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-29-24	Resumed	Wedbush	Outperform	$3 → $4
Sep-03-24	Initiated	Rodman & Renshaw	Buy	$7
Mar-08-22	Downgrade	JP Morgan	Overweight → Neutral
Jan-19-22	Downgrade	Goldman	Buy → Neutral	$29 → $6
Jul-01-21	Initiated	Raymond James	Outperform	$29
Jun-15-21	Initiated	BTIG Research	Buy	$25
Mar-04-21	Upgrade	Goldman	Neutral → Buy	$28 → $30
Feb-04-21	Initiated	Guggenheim	Buy	$25
Jan-25-21	Initiated	Wedbush	Outperform	$26
Jan-04-21	Upgrade	JP Morgan	Neutral → Overweight	$25 → $35
Dec-11-20	Initiated	Citigroup	Neutral	$28
Aug-14-20	Downgrade	JP Morgan	Overweight → Neutral	$25
Jun-25-20	Downgrade	Goldman	Buy → Neutral	$28
Mar-25-20	Initiated	Chardan Capital Markets	Buy	$30
Mar-24-20	Initiated	JP Morgan	Overweight	$25
Mar-24-20	Initiated	Goldman	Buy	$27
Mar-24-20	Initiated	Cowen	Outperform

Show Previous Ratings

Jan-10-25 07:00AM	Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates (GlobeNewswire)
Nov-30-24 06:55AM	Passage Bio assumed with an Outperform at Wedbush (TipRanks)
Nov-14-24 07:29AM	Passage Bio Achieves Milestones in Gene Therapy Trials (TipRanks)
Nov-13-24 07:00AM	Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -12.87%
Nov-06-24 07:00AM	Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference (GlobeNewswire)
07:00AM	Loading…
Oct-24-24 07:00AM	Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference (GlobeNewswire) +11.40%
Sep-23-24 09:36PM	Orbimed Advisors LLC Adjusts Stake in Passage Bio Inc (GuruFocus.com) -5.11%
07:00AM	Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-19-24 01:25AM	Orbimed Advisors LLC Reduces Stake in Passage Bio Inc (GuruFocus.com)
Sep-16-24 07:00AM	Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024) (GlobeNewswire) -9.45%
Sep-10-24 07:52AM	Passage Bio Welcomes Tom Kassberg to Board of Directors (GlobeNewswire) +6.06%
Aug-30-24 07:00AM	Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -5.96%
Aug-08-24 07:00AM	Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -5.22%
Aug-06-24 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-01-24 12:30PM	Jim Wilson, prominent gene therapy researcher, to depart UPenn (BioPharma Dive) +6.63%
07:00AM	Loading…
07:00AM	Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration (GlobeNewswire)
Jul-25-24 07:13AM	Passage Bio targets FDA to greenlight ALS gene therapy trial (Clinical Trials Arena) +6.23%
Jul-16-24 07:43AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients (GlobeNewswire)
Jun-18-24 09:35AM	Passage Bio (PASG) Loses -22.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -5.45%
Jun-05-24 07:30AM	Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-21-24 08:00AM	Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award (GlobeNewswire)
May-16-24 12:00PM	All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy (Zacks)
May-14-24 01:54PM	PASG Stock Earnings: Passage Bio Beats EPS for Q1 2024 (InvestorPlace) -10.47%
07:00AM	Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Apr-22-24 07:00AM	Passage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Mar-07-24 12:00PM	Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know (Zacks) -6.43%
Mar-06-24 01:52PM	PASG Stock Earnings: Passage Bio Beats EPS for Q4 2023 (InvestorPlace)
Mar-05-24 07:00AM	Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program (GlobeNewswire)
Mar-04-24 07:00AM	Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
07:00AM	Loading…
Feb-27-24 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.12%
Feb-01-24 07:09PM	7 Analyst-Backed Stocks With Promising 10-Bagger Potential (InvestorPlace) +5.13%
Jan-31-24 07:30AM	Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Dec-25-23 10:14PM	7 Nano-Cap Stocks That Pack a Serious Punch for Their Weight (InvestorPlace)
Dec-20-23 07:00AM	Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities (GlobeNewswire) +7.35%
Nov-17-23 04:30PM	Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Nov-13-23 07:00AM	Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Oct-30-23 07:00AM	Passage Bio to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference (GlobeNewswire) +6.91%
Oct-20-23 04:30PM	Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-25-23 07:00AM	Passage Bio to Present at Chardans 7th Annual Genetic Medicines Conference (GlobeNewswire)
Aug-11-23 10:04AM	Lab Notes: Almac Group starts work on $65M Montco expansion expected to create 355 jobs (American City Business Journals)
Aug-07-23 07:15AM	Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -5.11%
07:00AM	Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study (GlobeNewswire)
Aug-01-23 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jul-31-23 07:00AM	Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors (GlobeNewswire)
Jul-24-23 12:37PM	Passage Bio reduces staff by 26% in latest round of job cuts (American City Business Journals) -5.31%
Jul-06-23 11:17AM	12 Best Nano Cap Stocks To Buy Now (Insider Monkey)
Jun-05-23 07:00AM	Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
May-11-23 07:00AM	Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
May-04-23 07:00AM	Passage Bio Announces Recipient of Second Annual Tachi Yamada Scholarship Award (GlobeNewswire) +5.91%
Apr-21-23 04:01PM	Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-17-23 07:00AM	Passage Bio to Present at Chardans 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Mar-29-23 09:02AM	Is Passage Bio (NASDAQ:PASG) In A Good Position To Invest In Growth? (Simply Wall St.)
Mar-27-23 07:00AM	Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (GlobeNewswire)
Mar-08-23 07:14AM	Passage Bio, Inc. (NASDAQ:PASG) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-07-23 12:42AM	Q4 2022 Passage Bio Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-06-23 07:00AM	Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Mar-01-23 07:00AM	Passage Bio Seeks Pennsylvania College Student Candidates for Second Annual Tachi Yamada Scholarship Program (GlobeNewswire)
Feb-28-23 07:00AM	Passage Bio to Present at Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-27-23 07:00AM	Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023 (GlobeNewswire) +7.69%
Feb-24-23 07:00AM	Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium 2023 (GlobeNewswire) -7.87%
Feb-20-23 05:59PM	'We've turned the page': CEO says Passage Bio is building momentum after turbulent 2022 (American City Business Journals)
Feb-15-23 07:00AM	Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium 2023 (GlobeNewswire)
Jan-20-23 04:01PM	Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-07-23 07:39AM	After losing 67% in the past year, Passage Bio, Inc. (NASDAQ:PASG) institutional owners must be relieved by the recent gain (Simply Wall St.)
Dec-14-22 12:13PM	Passage Bio Stock Jumps After Gene Therapy Study In Lysosomal Storage Disorder (Benzinga) +9.65%
07:00AM	Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study (GlobeNewswire)
Nov-21-22 05:24AM	Estimating The Fair Value Of Passage Bio, Inc. (NASDAQ:PASG) (Simply Wall St.)
Nov-10-22 07:00AM	Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +10.83%
Nov-08-22 07:00AM	Passage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day (GlobeNewswire)
Nov-03-22 07:30AM	Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022 (GlobeNewswire)
Oct-14-22 04:01PM	Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.88%
Oct-11-22 12:25PM	Here's Why Passage Bio (NASDAQ:PASG) Must Use Its Cash Wisely (Simply Wall St.)
Oct-10-22 07:00AM	Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer (GlobeNewswire)
Sep-26-22 07:00AM	Passage Bio to Present at Chardans 6th Annual Genetic Medicines Conference (GlobeNewswire)
Aug-19-22 04:01PM	Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Aug-11-22 07:00AM	Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations (GlobeNewswire)
Aug-05-22 07:00AM	Passage Bio to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference (GlobeNewswire)
Aug-04-22 07:00AM	Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Jul-28-22 07:30AM	Passage Bio to Report Second Quarter 2022 Financial Results on August 4, 2022 (GlobeNewswire) -7.98%
Jul-21-22 04:01PM	Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-12-22 08:19AM	What Kind Of Investors Own Most Of Passage Bio, Inc. (NASDAQ:PASG)? (Simply Wall St.)
Jul-06-22 07:00AM	Passage Bio Appoints Michael Kamarck, Ph.D. to Board of Directors (GlobeNewswire)
Jun-09-22 07:30AM	Passage Bio to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference (GlobeNewswire)
Jun-08-22 07:30AM	Passage Bio Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy (GlobeNewswire)
Jun-01-22 10:19AM	Passage Bio and CEO Bruce Goldsmith part ways (American City Business Journals)
07:30AM	Passage Bio Announces Leadership Transition (GlobeNewswire)
May-20-22 04:01PM	Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.38% -6.44%
May-18-22 07:00AM	Passage Bio Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at ASGCT 25th Annual Meeting (GlobeNewswire) -5.35%
May-16-22 07:00AM	Passage Bio Reports First Quarter 2022 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -7.65%
May-09-22 07:00AM	Passage Bio to Report First Quarter 2022 Financial Results on May 16, 2022 (GlobeNewswire) -10.31%
May-04-22 10:55AM	Is Passage Bio (NASDAQ:PASG) In A Good Position To Invest In Growth? (Simply Wall St.) +13.78%
May-03-22 02:13PM	UPDATE - Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual Meeting (GlobeNewswire)
May-02-22 04:01PM	Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual Meeting (GlobeNewswire)
Apr-22-22 04:01PM	Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-29-22 07:00AM	Passage Bio Announces Publication of Preclinical Data that Support Ongoing Clinical Study of PBKR03 in Krabbe Disease (GlobeNewswire) +5.30%
Mar-28-22 07:00AM	Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-15-22 11:22AM	Passage Bio trims workforce by 13%, narrows R&D focus to extend cash runway (American City Business Journals)
11:12AM	Passage Bio To Cut Workforce, Prioritize R&D Programs To Reduce Operating Expenses (Benzinga)
07:00AM	Passage Bio Provides Update on Strategic Priorities and Extends Cash Runway (GlobeNewswire)

Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ORBIMED ADVISORS LLC	10% Owner	Jan 10 '25	Sale	0.66	126,209	83,298	7,131,636	Jan 14 05:17 PM
ORBIMED ADVISORS LLC	10% Owner	Jan 14 '25	Sale	0.60	79,024	47,414	7,034,626	Jan 14 05:17 PM
ORBIMED ADVISORS LLC	10% Owner	Jan 13 '25	Sale	0.64	17,986	11,511	7,113,650	Jan 14 05:17 PM
ORBIMED ADVISORS LLC	10% Owner	Jan 08 '25	Sale	0.68	75,007	51,005	7,257,845	Jan 08 06:09 PM
ORBIMED ADVISORS LLC	10% Owner	Jan 07 '25	Sale	0.71	52,536	37,301	7,332,852	Jan 08 06:09 PM
ORBIMED ADVISORS LLC	10% Owner	Jan 06 '25	Sale	0.77	19,481	15,000	7,385,388	Jan 08 06:09 PM
OrbiMed Private Investments VI	Stockholder	Jan 06 '25	Proposed Sale	0.83	1,140,740	945,673		Jan 06 04:57 PM
Lynx1 Capital Management LP	10% Owner	Dec 27 '24	Buy	0.65	373,645	241,038	9,256,953	Dec 31 04:05 PM
ORBIMED ADVISORS LLC	10% Owner	Dec 20 '24	Sale	0.60	230,321	138,193	7,404,869	Dec 26 04:34 PM
ORBIMED ADVISORS LLC	10% Owner	Dec 09 '24	Sale	0.84	54,181	45,512	7,643,285	Dec 11 05:32 PM
ORBIMED ADVISORS LLC	10% Owner	Dec 10 '24	Sale	0.80	8,015	6,412	7,635,270	Dec 11 05:32 PM
ORBIMED ADVISORS LLC	10% Owner	Dec 11 '24	Sale	0.80	80	64	7,635,190	Dec 11 05:32 PM
ORBIMED ADVISORS LLC	10% Owner	Dec 04 '24	Sale	0.79	76,200	60,198	7,718,369	Dec 06 07:07 PM
ORBIMED ADVISORS LLC	10% Owner	Dec 06 '24	Sale	0.82	20,903	17,140	7,697,466	Dec 06 07:07 PM
OrbiMed Private Investments VI	Stockholder	Dec 04 '24	Proposed Sale	0.89	2,985,518	2,657,111		Dec 04 07:03 PM
Worldwide Healthcare Trust PLC	Stockholder	Dec 04 '24	Proposed Sale	0.89	2,028,307	1,805,193		Dec 04 06:57 PM
Lynx1 Capital Management LP	10% Owner	Nov 25 '24	Buy	0.56	259,998	146,665	8,686,953	Nov 27 06:11 PM
Lynx1 Capital Management LP	10% Owner	Nov 26 '24	Buy	0.71	167,055	118,191	8,854,008	Nov 27 06:11 PM
Lynx1 Capital Management LP	10% Owner	Nov 27 '24	Buy	0.67	29,300	19,663	8,883,308	Nov 27 06:11 PM
ORBIMED ADVISORS LLC	10% Owner	Sep 19 '24	Sale	0.71	39,300	27,903	7,794,569	Sep 23 04:51 PM
ORBIMED ADVISORS LLC	10% Owner	Sep 17 '24	Sale	0.73	111,400	81,322	7,859,500	Sep 18 06:38 PM
ORBIMED ADVISORS LLC	10% Owner	Sep 16 '24	Sale	0.74	63,100	46,694	7,970,900	Sep 18 06:38 PM
ORBIMED ADVISORS LLC	10% Owner	Sep 18 '24	Sale	0.73	25,631	18,711	7,833,869	Sep 18 06:38 PM
Worldwide Healthcare Trust PLC	Owner	Sep 16 '24	Proposed Sale	0.81	241,328	194,752		Sep 16 08:38 PM
OrbiMed Private Investments VI	Owner	Sep 16 '24	Proposed Sale	0.81	927,572	748,551		Sep 16 08:36 PM
Borthwick Kathleen	SVP, INTERIM CFO	Feb 13 '24	Sale	0.97	1,470	1,426	28,466	Feb 13 07:36 PM
Forman Mark S	CHIEF MEDICAL OFFICER	Feb 13 '24	Sale	0.97	1,638	1,589	48,631	Feb 13 07:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PASG

Passage Bio Inc

Upgrade your FINVIZ experience